Abstract
In recent years, the medical treatment of inflammatory bowel diseases (IBD) has received more attention from clinicians, researchers and the pharmaceutical industry. Although the management of IBD has improved significantly since the introduction of anti-tumour necrosis factor (TNF) antibodies, a considerable proportion of patients have a poor response or a progressive loss of response to these agents. Fortunately, elucidating molecular pathways in IBD pathogenesis is opening avenues for the development of novel therapeutic strategies. Various biologicals and small molecules have been designed and evaluated in clinical trials in patients with IBD, demonstrating variable outcomes. Currently, several of these drugs are undergoing phase II trials. In this paper, we review conventional immunomodulators, anti-TNF agents and novel drugs that specifically target inflammatory mediators for the treatment of IBD.
| Original language | English |
|---|---|
| Pages (from-to) | 218-223 |
| Number of pages | 6 |
| Journal | European Gastroenterology and Hepatology Review |
| Volume | 7 |
| Issue number | 4 |
| Publication status | Published - 2012 |
Keywords
- Adhesion molecule blockers
- Anti-tumour necrosis factor (TNF) agents
- Biologicals
- Crohn's disease (CD)
- Immunomodulators
- Inflammatory bowel diseases (IBD)
- Small molecules
- Ulcerative colitis (UC)